A recent study found that CEBPA promotes castration-resistance and AR signaling in prostate cancer through a direct protein interaction with AR; this suggests that co-targeting CEBPA and AR may be one approach to block AR in either castration-resistant or enzalutamide-resistant tumors [35]. The gene discussed is AR; the disease is Familial prostate cancer.